A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
Denali Therapeutics Analyst Ratings
Denali Therapeutics Is Maintained at Overweight by JP Morgan
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $87
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Denali Therapeutics Initiated at Outperform by Baird
Denali Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)
Denali Therapeutics Maintains Strong Buy Rating Amid Setbacks, Fueled by Promising BBB Platform
Denali Therapeutics Initiated at Outperform by William Blair
Denali Therapeutics Analyst Ratings
William Blair Initiates Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $35
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
Denali Therapeutics Analyst Ratings
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
Denali Therapeutics (DNLI) Receives a Hold From Stifel Nicolaus